Teleflex Incorporated (TFX) — Business Overview

---

Executive Summary

Teleflex Incorporated (NYSE: TFX) is a global medical technology company that designs, manufactures, and markets single-use medical devices used primarily in hospital-based critical care and surgical procedures. Headquartered in Wayne, Pennsylvania and incorporated in Delaware, Teleflex has operated as a pure-play medical device company since 2011, following earlier divestitures of its commercial/industrial businesses and, in December 2023, its respiratory product lines to Medline.

The company is in the midst of a major corporate transformation. In February 2025, Teleflex announced a plan to separate into two independent public companies — a lower-growth, higher-margin RemainCo (Vascular, Interventional, and Surgical businesses) and a "NewCo" (Acute Care, Interventional Urology, and OEM businesses) to be distributed to shareholders tax-free. That plan has since evolved: on December 9, 2025, Teleflex signed definitive agreements to instead sell the NewCo businesses outright for roughly $2.0 billion in cash, rather than spin them off — the Acute Care and Interventional Urology units (including the flagship UroLift System) to Intersurgical Ltd., and the OEM business to private-equity sponsors Montagu and Kohlberg. Both transactions are expected to close in the second half of 2026 and have been reported as discontinued operations since Q4 2025. The transition has also brought leadership change: CEO Liam Kelly departed in January 2026, with Stuart Randle named Interim President and CEO and Stephen Klasko, M.D. named independent Chair.

Once the divestitures close, continuing-operations Teleflex will be a more focused, roughly $2+ billion revenue company built around vascular access, interventional, and surgical devices sold across the Americas, EMEA, and Asia Pacific.

---

1. Core Business Model & How They Work

Teleflex runs a classic single-use medical device model: design a device, obtain regulatory clearance, manufacture it at scale in a handful of global plants, and sell it through a direct sales force and distributors into hospitals, ambulatory surgical centers, and physician offices — where each unit is consumed during a single procedure and must be repurchased for the next one, producing durable, procedure-linked recurring demand.

[ R&D / Device Design ] -> [ Regulatory Clearance (FDA 510(k)/PMA, CE Mark) ] ->
[ Manufacturing (Czech Republic, Malaysia, Mexico, U.S.) ] ->
[ Direct Sales Force + Distributors ] -> [ Hospitals / ASCs / Physician Offices ] ->
[ Single-Use Procedure Consumption ] -> [ Repeat Purchase / Recurring Demand ]

Key Operational Drivers

1. Procedure-Linked, Recurring Revenue: Because nearly all core products are single-use and consumed during a procedure, demand tracks hospital procedure volumes rather than one-time capital equipment cycles.
2. Concentrated, Lower-Cost Manufacturing Footprint: Primary plants in the Czech Republic, Malaysia, Mexico, and the U.S. allow Teleflex to manufacture at scale while keeping landed costs competitive. Post-separation, the continuing company's footprint shrinks from 19 facilities to 7, as the other 12 move with the divested businesses.
3. Bolt-On M&A to Sharpen the Portfolio: Teleflex supplements organic growth with targeted acquisitions in higher-growth adjacencies — most notably the Vascular Intervention business of BIOTRONIK SE & Co. KG, which closed June 30, 2025 and expanded Teleflex's coronary and peripheral interventional offering.
4. Active Portfolio Management: Management has repeatedly reshaped the portfolio around higher-growth, higher-margin hospital-based franchises — divesting commercial/industrial lines (2011), respiratory (2023), and now Acute Care, Interventional Urology, and OEM (targeted H2 2026) — while concentrating capital in Vascular, Interventional, and Surgical.

---

2. Business Segments

Historically, Teleflex organized its product portfolio across Vascular Access, Interventional, Anesthesia/Acute Care, Surgical, Interventional Urology, and OEM categories, with revenue separately reported by geography (Americas, EMEA, Asia). The February 2025 separation announcement regrouped the product categories into two economic halves — a continuing operation and a to-be-divested operation — and as of Q4 2025 the latter is formally reported as discontinued operations.

                         +-------------------------------------------+
                         |            Teleflex Incorporated           |
                         |   NYSE: TFX -- FY2025 continuing-ops rev.   |
                         |              $1,992.7M (GAAP)                |
                         +--------------------+------------------------+
                                              |
              +--------------------------------+-------------------------------+
              v                                                               v
 +---------------------------------+                         +--------------------------------------+
 |   CONTINUING OPERATIONS          |                         |   DISCONTINUED OPERATIONS              |
 |   (go-forward Teleflex)           |                         |   (held for sale -- former "NewCo")     |
 |   ~$2.1B pro forma 2024 revenue    |                        |   ~$1.4B pro forma 2024 revenue          |
 +----------------+------------------+                         +-------------------+--------------------+
                  |                                                              |
      +-----------+------------+                               +-----------------+------------------+
      v            v           v                               v                 v                  v
  Vascular    Interventional  Surgical                     Acute Care    Interventional Urology    OEM
 (Arrow,      (BIOTRONIK VI,  (Weck, Titan SGS,            (airway /      (UroLift,                (contract-
  EZ-IO,       GuideLiner,     Pleur-Evac,                  anesthesia)    Barrigel)                 manufactured
  QuikClot)    MANTA,          KMedic, Pilling)             -> sold to     -> sold to                 devices)
                Turnpike)                                   Intersurgical  Intersurgical            -> sold to
                                                                                                        Montagu/Kohlberg

Geographically, revenue is still tracked across Americas, EMEA, and Asia, with EMEA and Asia growing faster than the Americas in 2025, aided in part by the BIOTRONIK acquisition's European base.

---

3. Product Portfolio

---

4. Competitive Landscape

Teleflex competes against far larger, more diversified medtech conglomerates in most categories, and against focused niche players in specific product lines. Its post-separation strategy is to compete as a tighter mid-cap specialist rather than a broad-line generalist.

 MEDICAL DEVICE COMPETITIVE POSITIONING
+----------------------------------------------------------------------------+
| High                                                                        |
|  ^          [Teleflex]                        [Boston Scientific]          |
|  V          (Vascular/Interventional            (Interventional Cardiology,|
|  A           focus post-separation)              Urology, Endoscopy)       |
|  S                                                                          |
|  C      [ICU Medical]                                        [BD]          |
|  /      (Infusion & vascular                        (Vascular access +     |
|  I       access specialist)                          diagnostics, global)  |
|  R                                                                          |
|  F   [Cook Medical]                                                        |
|  O   (Private, niche                                           [Medtronic] |
|  C    vascular/IR player)                            (Broad diversified    |
|  U                                                     device portfolio)   |
|  S  Low                                                                     |
|     +----------------------------------------------------------------->   |
|     Low           PORTFOLIO SCALE / DIVERSIFICATION                High   |
+----------------------------------------------------------------------------+

Competitors by Domain

• Vascular Access: Becton Dickinson (BD) and ICU Medical are the primary rivals in central-line and peripheral catheters; BD's scale and bundled infusion/diagnostics portfolio give it stronger group-purchasing-organization (GPO) leverage.
• Interventional / Coronary & Peripheral Vascular: Boston Scientific, Medtronic, and privately held Cook Medical compete directly in guide catheters, closure devices, and balloon/stent platforms — a market Teleflex deepened via the BIOTRONIK Vascular Intervention acquisition.
• Surgical: Competes against Medtronic, Johnson & Johnson (Ethicon), and B. Braun in ligation, closure, and stapling devices.
• Interventional Urology / Acute Care / OEM (divested): Prior to divestiture, UroLift competed against pharmaceutical BPH therapies and surgical alternatives from Boston Scientific; the OEM business competed against other contract manufacturers largely on cost — a lower-moat category consistent with its planned sale.

---

5. Strategic Strengths & Risks

Competitive Strengths

• Entrenched Clinical Workflows: Franchises like Arrow catheters and EZ-IO are embedded in hospital protocols and clinician training, creating real switching friction even where functionally similar alternatives exist.
• Sharper, Higher-Margin Post-Separation Portfolio: Shedding Acute Care, Interventional Urology, and OEM concentrates the company in Vascular, Interventional, and Surgical — the segments management has targeted for faster growth and a simpler operating model.
• Disciplined Portfolio Management & M&A: A long track record of divesting lower-growth businesses (commercial/industrial in 2011, respiratory in 2023, and now the former NewCo) while adding targeted capability (BIOTRONIK Vascular Intervention) shows active capital reallocation toward higher-return categories.

Strategic Risks & Vulnerabilities

Separation Execution Window
--------------------------------------------------------------------
  Dec 2025              H1 2026                 H2 2026 (target close)
  [Agreements signed] -> [Regulatory/closing conditions] -> [~$1.8B after-tax proceeds]

1. Divestiture Execution Risk: The Intersurgical and Montagu/Kohlberg transactions still require closing conditions and regulatory approvals ahead of their targeted second-half-2026 close; delay or renegotiation would prolong stranded costs and management distraction.
2. Leadership Transition: CEO Liam Kelly's January 2026 departure leaves Interim President and CEO Stuart Randle steering both the carve-out and the core business simultaneously, pending a permanent successor search.
3. Stranded Costs & Impairments: FY2026 guidance embeds roughly $90 million of stranded costs, and FY2025 already absorbed a $403.9 million goodwill impairment and a $100 million Titan SGS impairment plus held-for-sale write-downs that drove a GAAP net loss of $(905.6) million; the announced restructuring plan targets only $48–52 million of annual savings once fully phased in by mid-2028.
4. Demand Volatility in Legacy Lines: Preliminary January 2026 disclosures flagged softer U.S. and Asian demand for intra-aortic balloon pumps and catheters and delayed OEM purchase orders, trimming full-year revenue below prior guidance.
5. Scale Disadvantage vs. Diversified Peers: BD and Medtronic can cross-sell, out-invest in R&D, and negotiate more favorable GPO terms given their far larger, more diversified device portfolios.

---

6. Financial Overview

---

7. Summary Conclusion

Teleflex is a mid-cap medical device company mid-way through a self-directed transformation: having already exited respiratory products in 2023, it is now shedding its Acute Care, Interventional Urology, and OEM businesses — not through the tax-free spin-off originally announced in February 2025, but via roughly $2.0 billion in outright cash sales signed in December 2025 and expected to close in the second half of 2026. What remains will be a leaner, faster-growing company built around Vascular, Interventional, and Surgical franchises, freshly reinforced by the BIOTRONIK Vascular Intervention acquisition.

The near-term story is one of transition risk — a new interim CEO, stranded costs, and impairment-driven GAAP losses — set against a credible path to a simpler, higher-margin portfolio once the divestitures close and the restructuring plan's savings materialize by mid-2028.